[{"address1": "Wagistrasse 14", "city": "Schlieren", "zip": "8952", "country": "Switzerland", "phone": "41 44 755 77 00", "fax": "41 44 755 77 07", "website": "https://www.molecularpartners.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.", "fullTimeEmployees": 161, "companyOfficers": [{"maxAge": 1, "name": "Dr. Patrick  Amstutz Ph.D.", "age": 48, "title": "Co-Founder, CEO, Member of Management Board & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 786456, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael Tobias Stumpp Ph.D.", "age": 51, "title": "Co-Founder, Executive VP of Projects & Member of Management Board", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Hendriks", "title": "Senior VP of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Zurcher", "age": 48, "title": "COO & Member of Management Board", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Renate  Gloggner", "age": 53, "title": "Executive VP of People & Community and Member of Management Board", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Steiner Ph.D.", "title": "Senior Vice President of Research & Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Seth D. Lewis", "title": "Senior Vice President of Investor Relations, Communications & Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Pitzner", "title": "General Counsel, Compliance Officer, Senior VP Legal & Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pamela A. Trail Ph.D.", "age": 67, "title": "Strategic Consultant", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Goubier D.V.M., Ph.D.", "title": "Senior Vice President of Research & Early Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.9, "open": 6.53, "dayLow": 6.4, "dayHigh": 6.9, "regularMarketPreviousClose": 5.9, "regularMarketOpen": 6.53, "regularMarketDayLow": 6.4, "regularMarketDayHigh": 6.9, "beta": 0.614, "forwardPE": -3.0469482, "volume": 42162, "regularMarketVolume": 42162, "averageVolume": 24103, "averageVolume10days": 62610, "averageDailyVolume10Day": 62610, "marketCap": 215429056, "fiftyTwoWeekLow": 3.32, "fiftyTwoWeekHigh": 12.7, "priceToSalesTrailing12Months": 27.401304, "fiftyDayAverage": 5.4659, "twoHundredDayAverage": 5.07818, "currency": "USD", "enterpriseValue": 59277988, "floatShares": 17320979, "sharesOutstanding": 33194000, "sharesShort": 33492, "sharesShortPriorMonth": 29892, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.001, "heldPercentInstitutions": 0.02596, "shortRatio": 4.5, "shortPercentOfFloat": 0.0015, "impliedSharesOutstanding": 34225200, "bookValue": 4.688, "priceToBook": 1.3843856, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -57626000, "trailingEps": -2.02, "forwardEps": -2.13, "enterpriseToRevenue": 7.54, "enterpriseToEbitda": -0.971, "52WeekChange": 0.83852696, "SandP52WeekChange": 0.39389753, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MOLN", "underlyingSymbol": "MOLN", "shortName": "Molecular Partners AG", "longName": "Molecular Partners AG", "firstTradeDateEpochUtc": 1623850200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3b1227e2-09aa-3330-8282-b0e2c7493dad", "messageBoardId": "finmb_32677064", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.49, "targetHighPrice": 17.01, "targetLowPrice": 10.0, "targetMeanPrice": 13.51, "targetMedianPrice": 13.51, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 159126000, "totalCashPerShare": 4.795, "ebitda": -61049000, "totalDebt": 3049000, "quickRatio": 14.304, "currentRatio": 14.578, "totalRevenue": 7862000, "debtToEquity": 1.96, "revenuePerShare": 0.239, "returnOnAssets": -0.19312, "returnOnEquity": -0.31878, "freeCashflow": -38133000, "operatingCashflow": -61951000, "revenueGrowth": 2.737, "operatingMargins": -10.30045, "financialCurrency": "CHF", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]